Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning …
T Takagi, A Yamamuro, K Tamita, K Yamabe… - American heart …, 2003 - Elsevier
BACKGROUND: It has been reported that pioglitazone reduces neointimal hyperplasia after
balloon-induced vascular injury in an experimental model. METHODS: To determine
whether pioglitazone reduces neointimal tissue proliferation after coronary stent
implantation in patients with type 2 diabetes mellitus, we studied 44 stented lesions in 44
patients with diabetes mellitus who underwent successful coronary stent implantation. Study
patients were randomized into 2 groups: the pioglitazone group (23 patients with 23 lesions) …
balloon-induced vascular injury in an experimental model. METHODS: To determine
whether pioglitazone reduces neointimal tissue proliferation after coronary stent
implantation in patients with type 2 diabetes mellitus, we studied 44 stented lesions in 44
patients with diabetes mellitus who underwent successful coronary stent implantation. Study
patients were randomized into 2 groups: the pioglitazone group (23 patients with 23 lesions) …
Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non–insulin dependent diabetes mellitus: a serial intravascular …
T Takagi, T Akasaka, A Yamamuro, Y Honda… - Journal of the American …, 2000 - jacc.org
OBJECTIVES The aim of the present study was to determine whether troglitazone reduces
neointimal tissue proliferation after coronary stent implantation in patients with non–insulin
dependent diabetes mellitus (NIDDM). BACKGROUND Increased in-stent restenosis in
patients with diabetes mellitus is due to accelerated neointimal tissue proliferation after
coronary stent implantation. Troglitazone inhibits intimal hyperplasia in experimental animal
models. METHODS We studied 62 stented lesions in 52 patients with plasma glucose levels …
neointimal tissue proliferation after coronary stent implantation in patients with non–insulin
dependent diabetes mellitus (NIDDM). BACKGROUND Increased in-stent restenosis in
patients with diabetes mellitus is due to accelerated neointimal tissue proliferation after
coronary stent implantation. Troglitazone inhibits intimal hyperplasia in experimental animal
models. METHODS We studied 62 stented lesions in 52 patients with plasma glucose levels …